Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
…
Next ›
Last »
Saving Part D: MedPAC Debates Ways To Make Stand-Alone Plans More Viable; Warns That Future Of Traditional Medicare May Be At Stake
April 14, 2025
Fixing Biosimilars: Stelara Will Be Test Of Price Negotiation Impact; FDA Cuts May Have Significant Adverse Effect At Tough Time For Sector
April 14, 2025
“A Slow Moving Catastrophe”: FDA Layoffs Will Result In Less Guidance And Less Flexibility, Ex-Leaders Suggest; Cell/Gene Therapy Could Be A Bright Spot
April 14, 2025
Prevision Policy Clips | Digital Health Technologies In Clinical Trials: FDA Viewpoint Posted In JAMA
April 14, 2025
FDA “Five-Office” Reorg Proposal Criticized By Former Senior Officials; Regulatory Work Is Too Specialized For A “Big Team Of Generalists”
April 11, 2025
RFK At FDA: “Dissidents Will Be Listened To,” HHS Secretary Kennedy Says; Commissioner Makary Calls For “More Teamwork,” Less “Individual Empires”
April 11, 2025
Prevision Policy Clips | FDA Animal Testing Alternatives “Roadmap” Sets Three-Year Agenda
April 11, 2025
FDA To Phase Out Animal Testing For Monoclonals, FDA Commissioner Makary Says; Pilot Test In 2025 Aims To Lead To Broader Changes As “NAM” Process Moves Forward
April 10, 2025
HHS Drug Shortage Policy Reset: Trump Administration Urged By GAO To Focus On Coordination At Department Level; Report Provides Update On FDA Activities As Of 2024
April 10, 2025
Prevision Policy Clips | GLP-1 Agonist Coverage In Medicaid/Medicare: “Regulatory Framework” Still Under Consideration
April 10, 2025
FDA Rare Disease “Hub” Is Moving Forward With Agenda To Improve Consistency And Coordination Amid Agency Changes
April 9, 2025
FDA Oversight Of Compounded GLP-1 Products Urged By Former Commissioner Kessler In House Hearing On “Illicit” Products
April 9, 2025
FDA Generics Office Urges Renewed Focus On Data Integrity At Annual Update Meeting; Speakers Demonstrate Commitment To GDUFA Goals Amid Restructuring
April 9, 2025
Prevision Policy Clips | Hybrid Work Returning For FDA Reviewers?
April 9, 2025
House E&C Leadership Commits To Seeing PBM Reform Through; Other Health Measures Must Garner Similarly Strong Bipartisan Support
April 8, 2025
Prevision Policy Clips | “A Slow Moving Catastrophe”: Ex-FDA Leaders Paint Dark Picture
April 8, 2025
Prevision Policy Clips | CMS Drops Obesity Drug Coverage Proposal From Final Part D Update Rule
April 7, 2025
PBM Reforms Remain Live Topic On Capitol Hill While FTC Chaos Stalls Insulin Case
April 4, 2025
Imagining A Five-Office FDA: HHS Reorg Plan Could Merge All Product Centers Into One; Enforcement, Policy, Strategy, Admin Would Be Other Four
April 4, 2025
Prevision Policy Clips | Concepts Of A Plan? FDA “Streamlining” Will Result In “Five Shared Services Offices,” HHS Says
April 4, 2025
Generic Drug Competition/Patent Bills Still Have Bipartisan Backing In The Senate; Product “Hopping” And “Sham” Petitions Are Not Unanimous In Judiciary Committee Mark-Up
April 3, 2025
FDA Cuts May Impact Complex Generic Reviews, Inspections Despite Intent To Keep Applications Moving, Former Commissioner Gottlieb Says
April 3, 2025
Prevision Policy Clips | Novavax COVID Vaccine BLA Poses Early “Test” For Commissioner Martin Makary
April 3, 2025
Makary Introduces Himself To FDA Staff: “Our Country Needs You…I Will Do My Best” To Assure Resources; COVID Response Critic Hoeg Joins As Special Advisor
April 2, 2025
MAHA Vision For FDA Includes New Pathways For “Root-Cause” Treatments, But Not Traditional Big Pharma; HHS Advisor Means Says Layoffs Reflect “Failure” Of Agencies
April 2, 2025
1
2
3
4
5
…
Next ›
Last »